Phase I Study of MEDI-534 of a Live, Attenuated Intranasal Vaccine Against Respiratory Syncytial Virus and Parainfluenza-3 Virus in Seropositive Children


A live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine was evaluated in healthy respiratory syncytial virus/parainfluenza virus type 3 seropositive children aged 1 to 9 years. Three cohorts of 40 children were randomized 1:1 to receive 104, 105 or 106 median tissue culture infectious dose50 MEDI-534 vaccine of placebo. The vaccine\u27s safety profile was similar to placebo, no viral shedding was detected, and the vaccine was minimally immunogenic

Similar works

Full text


Marshall University

Provided a free PDF
oaioai:mds.marshall.edu:int_med-1011Last time updated on 10/29/2019View original full text link

This paper was published in Marshall University.

Having an issue?

Is data on this page outdated, violates copyrights or anything else? Report the problem now and we will take corresponding actions after reviewing your request.